Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease

GUIDELINE TITLE
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.

BIBLIOGRAPHIC SOURCE(S)
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda (MD): Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2009. 93 p. [447 references]

GUIDELINE STATUS
This is the current release of the guideline.

This guideline updates a previous version: Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda (MD): Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2008. 94 p. [435 references]

At the GOLD Science Committee meeting in September 2009, there was unanimous agreement that a revised document should be prepared for release in 2011.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT
Note from the National Guideline Clearinghouse: This guideline references a drug(s)/intervention(s) for which important revised regulatory and/or warning information has been released.

July 1, 2009 - Chantix or Champix (Varenicline) and Zyban or Wellbutrin (bupropion or amfebutamone): The U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients that it has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed Warnings and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products. These symptoms include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide.

open here to see the full-text:
http://www.guideline.gov/summary/summary.aspx?ss=15&doc_id=15555&nbr=&string=